Experimental drug shows promise for Tough-to-Treat lymphoma

NCT ID NCT03793140

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called CPI-613 in people with relapsed or hard-to-treat Burkitt lymphoma or high-grade B-cell lymphoma. About 24 participants aged 12 and older who have not responded to at least one prior treatment will receive the drug. The goal is to see if the drug can shrink or control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-GRADE B-CELL LYMPHOMA WITH REARRANGEMENTS OF MYC AND BCL2 AND/OR BCL6 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Burkitt lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement leukemia lymphoma plasmablastic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA LYMPHOMA

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Md Anderson Cancer Center

Houston, Texas, 77030, United States
Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
University of Pennsylvania (Data Collection Only)

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.